<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://ajprenal.physiology.org">
<title>AJP: Renal Physiology current issue</title>
<link>http://ajprenal.physiology.org</link>
<description>AJP: Renal Physiology RSS feed -- current issue</description>
<prism:eIssn>1522-1466</prism:eIssn>
<prism:coverDisplayDate>Jul  1 2008 12:00:00:000AM</prism:coverDisplayDate>
<prism:publicationName>AJP: Renal Physiology</prism:publicationName>
<prism:issn>0363-6127</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F1?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F12?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F18?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/full/295/1/F27?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F29?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/full/295/1/F35?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F37?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/full/295/1/F42?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F44?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F53?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F60?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F73?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F82?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F91?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F100?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F108?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F118?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F128?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F137?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F145?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F153?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F165?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F171?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F179?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F192?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F202?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F215?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F226?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F235?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F247?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F253?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F264?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F272?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F283?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F290?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F295?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F300?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F310?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F315?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/full/295/1/F322?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://ajprenal.physiology.org/icons/banner/title.gif" />
</channel>

<image rdf:about="http://ajprenal.physiology.org/icons/banner/title.gif">
<title>AJP: Renal Physiology</title>
<url>http://ajprenal.physiology.org/icons/banner/title.gif</url>
<link>http://ajprenal.physiology.org</link>
</image>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F1?rss=1">
<title><![CDATA[Exploring mechanisms involved in renal tubular sensing of mechanical stretch following ureteric obstruction]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F1?rss=1</link>
<description><![CDATA[ 
<P>Tubular mechanical stretch is the key primary insult in obstructive nephropathy. This review addresses how the renal tubular epithelium senses and responds to mechanical stretch. Using data from renal and nonrenal systems, we describe how sensing of stretch initially occurs via the activation of ion channels and subsequent increases in intracellular calcium levels. Calcium influxes activate a number of adaptive and proinjury responses. Key among these are <I>1</I>) the activation of Rho, consequent cytoskeletal rearrangements, and downstream increases in focal adhesion assembly; and <I>2</I>) phospholipase activation and resultant mitogen-activated protein kinase activation. These early signaling events culminate in adaptive cellular coupling to the extracellular matrix, a process termed the cell strengthening response. Direct links can be made between increased expression of genes involved in the development of obstructive nephropathy and initial sensing of mechanical stretch. The review illustrates the repercussions of mechanical stretch as a renal stress stimulus, specific to ureteric obstruction, and provides an insight into how tubular responses to mechanical stretch are ultimately implicated in the development of obstructive nephropathy.</P>
]]></description>
<dc:creator><![CDATA[Quinlan, M. R., Docherty, N. G., Watson, R. W. G., Fitzpatrick, J. M.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00576.2007</dc:identifier>
<dc:title><![CDATA[Exploring mechanisms involved in renal tubular sensing of mechanical stretch following ureteric obstruction]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F11</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F1</prism:startingPage>
<prism:section>INVITED REVIEWS</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F12?rss=1">
<title><![CDATA[New insights into the function of the Wilms tumor suppressor gene WT1 in podocytes]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F12?rss=1</link>
<description><![CDATA[ 
<P>The Wilms tumor suppressor gene <I>WT1</I> is essential for early urogenital development: homozygous mutations in <I>WT1</I> result in embryonic lethality due to a failure in the development of kidneys and gonads. In the adult kidney, WT1 expression is limited to the glomerular podocytes. Several human nephrotic diseases arise from mutations of the <I>WT1</I> gene, including mutations that affect its zinc-fingers and alternative splicing of +/&ndash;KTS isoforms. These include WAGR (for Wilms tumor, aniridia, genitourinary anomalies, and mental retardation), and Frasier and Denys-Drash syndromes. Recent advances including the development of transgenic mouse models and conditionally immortalized podocyte cell lines are beginning to shed light on WT1's crucial role in podocyte function.</P>
]]></description>
<dc:creator><![CDATA[Morrison, A. A., Viney, R. L., Saleem, M. A., Ladomery, M. R.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00597.2007</dc:identifier>
<dc:title><![CDATA[New insights into the function of the Wilms tumor suppressor gene WT1 in podocytes]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F17</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F12</prism:startingPage>
<prism:section>INVITED REVIEWS</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F18?rss=1">
<title><![CDATA[Regulation of epithelial sodium transport by promyelocytic leukemia zinc finger protein]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F18?rss=1</link>
<description><![CDATA[ 
<P>Aldosterone is the principal regulator of Na homeostasis, and thereby blood pressure. One of the main targets of aldosterone is the epithelial Na channel (ENaC) located in the apical membrane of target cells. Previous studies identified several genes involved in the regulation of ENaC such as SGK1; however, SGK1 knockout mice have only a mild salt-losing phenotype, indicating that further genes must be involved in the action of aldosterone. In our search for further aldosterone-regulated genes, we discovered that aldosterone, at physiological concentrations, induces the expression of the promyelocytic leukemia zinc finger protein (PLZF) in renal cortical collecting duct (CCD) cell lines that stably express mineralocorticoid receptors (MRs). This effect is rapid and does not require de novo protein synthesis, suggesting a direct action. Surprisingly, stable overexpression of human or mouse PLZF isoforms significantly decreased transepithelial Na transport in CCD cells while having no effect on the integrity of the monolayers. In parallel with the decline in Na transport, PLZF suppressed the mRNA levels of &beta;- and -ENaC subunits. These observations suggest that PLZF is a negative regulator of ENaC in renal epithelial cells and might be part of a negative feedback loop that limits aldosterone's stimulatory effects on sodium reabsorption.</P>
]]></description>
<dc:creator><![CDATA[Naray-Fejes-Toth, A., Boyd, C., Fejes-Toth, G.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00573.2007</dc:identifier>
<dc:title><![CDATA[Regulation of epithelial sodium transport by promyelocytic leukemia zinc finger protein]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F26</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F18</prism:startingPage>
<prism:section>CALL FOR PAPERS</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/full/295/1/F27?rss=1">
<title><![CDATA[Programming of hypertension: the nervous kidney]]></title>
<link>http://ajprenal.physiology.org/cgi/content/full/295/1/F27?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Vehaskari, V. M.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.90270.2008</dc:identifier>
<dc:title><![CDATA[Programming of hypertension: the nervous kidney]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F28</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F27</prism:startingPage>
<prism:section>EDITORIAL FOCUS</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F29?rss=1">
<title><![CDATA[Effect of renal denervation on prenatal programming of hypertension and renal tubular transporter abundance]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F29?rss=1</link>
<description><![CDATA[ 
<P>Prenatal glucocorticoids are often administered to pregnant women to accelerate pulmonary maturation. We have demonstrated that administration of dexamethasone during specific periods of pregnancy in the rat causes hypertension in the offspring when they are studied as adults. The purpose of the present study was to determine whether the hypertension due to prenatal dexamethasone was mediated by renal nerves. We administered dexamethasone to rats daily for 4 days between <I>days 15</I> and <I>18</I> of gestation. Rats underwent bilateral renal denervation or sham operation at 6 wk of age, and blood pressure was measured at 8 wk of age. Prenatal dexamethasone in the sham operation group resulted in an increase in blood pressure compared with vehicle-treated sham controls (134 &plusmn; 3 vs. 145 &plusmn; 3 mmHg, <I>P</I> &lt; 0.05). Renal denervation did not affect blood pressure significantly in the prenatal vehicle-treated control group but resulted in normalization in blood pressure in the prenatal dexamethasone group and (130 &plusmn; 3 and 128 &plusmn; 5 mmHg, respectively). Prenatal dexamethasone increased type 3 Na<SUP>+</SUP>/H<SUP>+</SUP> exchanger (NHE3), Na<SUP>+</SUP>-K<SUP>+</SUP>-2Cl<SUP>&ndash;</SUP> cotransporter (NKCC2), and Na<SUP>+</SUP>-Cl<SUP>&ndash;</SUP> cotransporter (NCC), but not -, &beta;-, and -epithelial Na<SUP>+</SUP> channel (ENaC) protein abundance compared with controls. The increase in NHE3, NKCC2, and NCC protein abundance by prenatal dexamethasone was not seen in 8-wk-old rats 2 wk after renal denervation. Renal denervation did not affect NHE3, NKCC2, and NCC protein abundance in prenatal vehicle-treated animals. This study is consistent with renal nerves playing a role in mediating the hypertension by prenatal programming by dexamethasone.</P>
]]></description>
<dc:creator><![CDATA[Dagan, A., Kwon, H. M., Dwarakanath, V., Baum, M.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00123.2008</dc:identifier>
<dc:title><![CDATA[Effect of renal denervation on prenatal programming of hypertension and renal tubular transporter abundance]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F34</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F29</prism:startingPage>
<prism:section>EDITORIAL FOCUS</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/full/295/1/F35?rss=1">
<title><![CDATA[Modulation of adenosine receptor expression in the proximal tubule: a novel adaptive mechanism to regulate renal salt and water metabolism]]></title>
<link>http://ajprenal.physiology.org/cgi/content/full/295/1/F35?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Castrop, H.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.90299.2008</dc:identifier>
<dc:title><![CDATA[Modulation of adenosine receptor expression in the proximal tubule: a novel adaptive mechanism to regulate renal salt and water metabolism]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F36</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F35</prism:startingPage>
<prism:section>EDITORIAL FOCUS</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F37?rss=1">
<title><![CDATA[Low salt intake increases adenosine type 1 receptor expression and function in the rat proximal tubule]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F37?rss=1</link>
<description><![CDATA[ 
<P>Adenosine mediates Na<SUP>+</SUP> reabsorption in the proximal tubule (PT) and other segments by activating adenosine type 1 receptors (A1-AR). We tested the hypothesis that A1-AR in the PT is regulated by salt intake and participates in the kidney adaptation to changes in salt intake. Absolute fluid reabsorption (<I>J</I><SUB>v</SUB>) was measured by direct in vivo microperfusion and recollection in rats maintained on low (LS; 0.03% Na, wt/wt)-, normal (NS; 0.3% Na)-, and high-salt (HS; 3.0% Na) diets for 1 wk. The effect of microperfusion of BG9719 a highly selective inhibitor of A1-ARs or adenosine deaminase (AD), which metabolizes adenosine, was measured in each group. <I>J</I><SUB>v</SUB> was higher in PT from LS rats (LA: 2.8 &plusmn; 0.2 vs. NS: 2.1 &plusmn; 0.2 nl&middot;min<SUP>&ndash;1</SUP>&middot;mm<SUP>&ndash;1</SUP>, <I>P</I> &lt; 0.001). <I>J</I><SUB>v</SUB> in HS rats was not different from NS. BG9719 reduced <I>J</I><SUB>v</SUB> in LS rats by 66 &plusmn; 6% (LS: 2.8 &plusmn; 0.2 vs LS+CVT: 1.3 &plusmn; 0.3 nl&middot;min<SUP>&ndash;1</SUP>&middot;mm<SUP>&ndash;1</SUP>, <I>P</I> &lt; 0.001), which was greater than its effect in NS (45 &plusmn; 4%) or HS (41 &plusmn; 4%) rats. AD reduced <I>J</I><SUB>v</SUB> similarly, suggesting that A1-ARs are activated by local production of adenosine. Expression of A1-AR mRNA and protein was higher (<I>P</I> &lt; 0.01) in microdissected PTs in LS rats compared with NS and HS. We conclude that A1-ARs in the PT are increased by low salt intake and that A1-AR participates in the increased PT reabsorption of solute and fluid in response to low salt intake.</P>
]]></description>
<dc:creator><![CDATA[Kulick, A., Panico, C., Gill, P., Welch, W. J.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00061.2008</dc:identifier>
<dc:title><![CDATA[Low salt intake increases adenosine type 1 receptor expression and function in the rat proximal tubule]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F41</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F37</prism:startingPage>
<prism:section>EDITORIAL FOCUS</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/full/295/1/F42?rss=1">
<title><![CDATA[Cisplatin-induced cytoxicity: is the nucleus relevant?]]></title>
<link>http://ajprenal.physiology.org/cgi/content/full/295/1/F42?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Sheikh-Hamad, D.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.90293.2008</dc:identifier>
<dc:title><![CDATA[Cisplatin-induced cytoxicity: is the nucleus relevant?]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F43</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F42</prism:startingPage>
<prism:section>EDITORIAL FOCUS</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F44?rss=1">
<title><![CDATA[Cytoplasmic initiation of cisplatin cytotoxicity]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F44?rss=1</link>
<description><![CDATA[ 
<P>The mechanism of action of cisplatin as a chemotherapeutic agent has been attributed to DNA binding, while its mechanism of action as a nephrotoxin is unresolved. Only ~1% of intracellular cisplatin interacts with DNA, primarily forming intrastrand cross-linked adducts, and many studies have implicated both nuclear and cytoplasmic causes of cisplatin-induced death in cultured cells. We have demonstrated that cisplatin cytotoxicity depends on cdk2 activity, which is at least partly through the cdk2-E2F1 pathway. The mechanism of the dependency on cdk2, and whether cdk2 activation of E2F1 represents the only cell death pathway involved, is still unclear. Our previous work showed that deletion of the nuclear localization signal from p21<SUP>WAF1/CIP1</SUP>, a cdk2 inhibitor, did not alter its protective action against cisplatin cytotoxicity. Active cdk2-cyclin complexes are localized in both the nucleus and cytoplasm, and it was reported that cdk2 translocated to the cytoplasm after an apoptotic stimulus. Herein, we show that cisplatin caused cell death in enucleated mouse kidney proximal tubule cells (TKPTS), which was prevented by cdk2 inhibition. Also, we localized cytoplasmic cdk2 to both the endoplasmic reticulum (ER) and Golgi compartments, and ER stress was blocked by specific cdk2 inhibition. We conclude that cisplatin can induce nuclear independent apoptosis, cisplatin cytotoxicity can be initiated by cytoplasmic events, and cytoplasmic cdk2 plays an important role in apoptosis signaling.</P>
]]></description>
<dc:creator><![CDATA[Yu, F., Megyesi, J., Price, P. M.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00593.2007</dc:identifier>
<dc:title><![CDATA[Cytoplasmic initiation of cisplatin cytotoxicity]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F52</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F44</prism:startingPage>
<prism:section>EDITORIAL FOCUS</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F53?rss=1">
<title><![CDATA[Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-{beta}, and fibronectin with concomitant increase in nitric oxide bioavailability]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F53?rss=1</link>
<description><![CDATA[ 
<P>Clinical and experimental studies have provided evidence suggesting that statins exert renoprotective effects. To investigate the mechanisms by which statins may exert renoprotection, we utilized the hypertensive Dahl salt-sensitive (DS) rat model, which manifests cardiovascular and renal injury linked to increased angiotensin II-dependent activation of NADPH oxidase and decreased nitric oxide (NO) bioavailability. DS rats given high salt diet (4% NaCl) for 10 wk exhibited hypertension [systolic blood pressure (SBP) 200 &plusmn; 8 vs. 150 &plusmn; 2 mmHg in normal salt diet (0.5% NaCl), <I>P</I> &lt; 0.05], glomerulosclerosis, and proteinuria (158%). This was associated with increased renal oxidative stress demonstrated by urinary 8-F<SUB>2</SUB>-isoprostane excretion and NADPH oxidase activity, increased protein expression of transforming growth factor (TGF)-&beta; (63%) and fibronectin (181%), increased mRNA expression of the proinflammatory molecules monocyte chemoattractant protein-1 (MCP-1) and lectin-like oxidized LDL receptor-1 (LOX-1), as well as downregulation of endothelial NO synthase (eNOS) activity (&ndash;44%) and protein expression. Return to normal salt had no effect on SBP or any of the measured parameters. Atorvastatin (30 mg&middot;kg<SUP>&ndash;1</SUP>&middot;day<SUP>&ndash;1</SUP>) significantly attenuated proteinuria and glomerulosclerosis and normalized renal oxidative stress, TGF-&beta;1, fibronectin, MCP-1 and LOX-1 expression, and eNOS activity and expression. Atorvastatin-treated rats showed a modest reduction in SBP that remained in the hypertensive range (174 &plusmn; 8 mmHg). Atorvastatin combined with removal of high salt normalized SBP and proteinuria. These findings suggest that statins mitigate hypertensive renal injury by restoring the balance among NO, TGF-&beta;1, and oxidative stress and explain the added renoprotective effects observed in clinical studies using statins in addition to inhibitors of the renin-angiotensin system.</P>
]]></description>
<dc:creator><![CDATA[Zhou, M.-S., Schuman, I. H., Jaimes, E. A., Raij, L.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00041.2008</dc:identifier>
<dc:title><![CDATA[Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-{beta}, and fibronectin with concomitant increase in nitric oxide bioavailability]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F59</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F53</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F60?rss=1">
<title><![CDATA[VEGF receptors and neuropilins are expressed in the urothelial and neuronal cells in normal mouse urinary bladder and are upregulated in inflammation]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F60?rss=1</link>
<description><![CDATA[ 
<P>Recent evidence supports a role for vascular endothelium growth factor (VEGF) signaling in bladder inflammation. However, it is not clear what bladder cells are targeted by VEGF. Therefore, we determined the nature of cells responding to VEGF in normal and inflamed bladders by tagging such cells in vivo with a targeted fluorescent tracer, scVEGF/Cy, an engineered single-chain VEGF labeled with Cy5.5 dye, which identifies cells with accessible and functionally active VEGF receptors. Inflammation was induced by intravesical instillation of PAR-activating peptides or BCG. In vivo NIRF imaging with intravenously injected scVEGF/Cy revealed accumulation of the tracer in the control mouse bladder and established that inflammation increased the steady-state levels of tracer uptake. Ex vivo colocalization of Cy5.5 dye revealed that in normal and at a higher level in inflamed bladder, accumulation of scVEGF/Cy occurs in both urothelial and ganglial cells, expressing VEGF receptors VEGFR-1 and VEGFR-2, as well as VEGF coreceptors neuropilins (NRP) NRP1 and NRP2. PCR results indicate that the messages for VEGF-Rs and NRPs are present in the bladder mucosa and ChIP/QPCR analysis indicated that inflammation induced upregulation of genes encoding VEGFRs and NRPs. Our results strongly suggest new and blossoming VEGF-driven processes in bladder urothelial cells and ganglia in the course of inflammation. We expect that molecular imaging of the VEGF pathway in the urinary tract by receptor-mediated cell tagging in vivo will be useful for clinical diagnosis and therapeutic monitoring, and will help to accelerate the development of bladder-targeting drugs and treatments.</P>
]]></description>
<dc:creator><![CDATA[Saban, M. R., Backer, J. M., Backer, M. V., Maier, J., Fowler, B., Davis, C. A., Simpson, C., Wu, X.-R., Birder, L., Freeman, M. R., Soker, S., Hurst, R. E., Saban, R.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00618.2007</dc:identifier>
<dc:title><![CDATA[VEGF receptors and neuropilins are expressed in the urothelial and neuronal cells in normal mouse urinary bladder and are upregulated in inflammation]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F72</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F60</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F73?rss=1">
<title><![CDATA[Aldosterone induces mesangial cell apoptosis both in vivo and in vitro]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F73?rss=1</link>
<description><![CDATA[ 
<P>Both clinical and experimental reports indicate that aldosterone contributes to the progression of renal failure independent of its hemodynamic effects. In the present study, we evaluated effect of aldosterone on human mesangial cell (MC) growth. Aldosterone induced apoptotic and mitogenic effects on MCs. Aldosterone promoted MC apoptosis in a dose- and time-dependent manner. Spironolactone, a mineralocorticoid receptor antagonist, inhibited aldosterone-induced MC apoptosis. Similarly, antioxidants and free radical scavengers partially attenuated proapoaptotic effects of aldosterone. Aldosterone also enhanced dephosphorylation of phospho-Bad and accumulation of cytosolic cytochrome <I>c</I> in MCs. In in vivo studies, rats were randomly assigned to receive normal saline, aldosterone, or eplerenone + aldosterone for 28 days. Systolic blood pressure, urinary albumin excretion rate, serum creatinine, and aldosterone were measured. Aldosterone-infused rats developed elevated systolic blood pressure and albuminuria when compared with control rats. Aldosterone-treated rats also showed greater numbers of apoptosed MCs. This proapoptotic effect of aldosterone was inhibited by eplerenone, a selective aldosterone antagonist. These findings suggest that aldosterone, besides its hemodynamic effects, may also directly contribute to the occurrence of MC apoptosis.</P>
]]></description>
<dc:creator><![CDATA[Mathew, J. T., Patni, H., Chaudhary, A. N., Liang, W., Gupta, A., Chander, P. N., Ding, G., Singhal, P. C.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00435.2007</dc:identifier>
<dc:title><![CDATA[Aldosterone induces mesangial cell apoptosis both in vivo and in vitro]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F81</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F73</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F82?rss=1">
<title><![CDATA[Silencing megalin and cubilin genes inhibits myeloma light chain endocytosis and ameliorates toxicity in human renal proximal tubule epithelial cells]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F82?rss=1</link>
<description><![CDATA[ 
<P>Using target-specific short interfering (si) RNAs, we silenced the tandem endocytic receptors megalin and cubilin genes in cultured human renal proximal tubule epithelial cells. Transfection by siRNA resulted in up to 90% suppression of both megalin and cubilin protein and mRNA expression. In HK-2 cells exposed to -light chain for up to 24 h, light chain endocytosis was reduced in either megalin- or cubilin-silenced cells markedly but incompletely. Simultaneous silencing of both the cubilin and megalin genes, however, resulted in near-complete inhibition of light chain endocytosis, as determined by measuring -light chain protein concentration in cell cytoplasm and by flow cytometry using FITC-labeled -light chain. In these cells, light chain-induced cytokine responses (interleukin-6 and monocyte chemoattractant protein-1) and epithelial-to-mesenchymal transition as well as the associated cellular and morphological alterations were also markedly suppressed. The results demonstrate that light chain endocytosis is predominantly mediated by the megalin-cubilin tandem endocytic receptor and identify endocytosis as a key step in light chain cytotoxicity. Blocking light chain endocytosis prevents its nephrotoxic effects on human kidney proximal tubule cells.</P>
]]></description>
<dc:creator><![CDATA[Li, M., Balamuthusamy, S., Simon, E. E., Batuman, V.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00091.2008</dc:identifier>
<dc:title><![CDATA[Silencing megalin and cubilin genes inhibits myeloma light chain endocytosis and ameliorates toxicity in human renal proximal tubule epithelial cells]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F90</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F82</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F91?rss=1">
<title><![CDATA[Human FXYD2 G41R mutation responsible for renal hypomagnesemia behaves as an inward-rectifying cation channel]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F91?rss=1</link>
<description><![CDATA[ 
<P>A mutation in the human FXYD2 polypeptide (Na-K-ATPase  subunit) that changes a conserved transmembrane glycine to arginine is linked to dominant renal hypomagnesemia. <I>Xenopus laevis</I> oocytes injected with wild-type FXYD2 or the mutant G41R cRNAs expressed large nonselective ion currents. However, in contrast to the wild-type FXYD2 currents, inward rectifying cation currents were induced by hyperpolarization pulses in oocytes expressing the G41R mutant. Injection of EDTA into the oocyte removed inward rectification in the oocytes expressing the mutant, but did not alter the nonlinear current-voltage relationship of the wild-type FXYD2 pseudo-steady-state currents. Extracellular divalent ions, Ca<SUP>2+</SUP> and Ba<SUP>2+</SUP>, and trivalent cations, La<SUP>3+</SUP>, blocked both the wild-type and mutant FXYD2 currents. Site-directed mutagenesis of G41 demonstrated that a positive charge at this site is required for the inward rectification. When the wild-type FXYD2 was expressed in Madin-Darby canine kidney cells, the cells in the presence of a large apical-to-basolateral Mg<SUP>2+</SUP> gradient and at negative potentials had an increase in transepithelial current compared with cells expressing the G41R mutant or control transfected cells. Moreover, this current was inhibited by extracellular Ba<SUP>2+</SUP> at the basolateral surface. These results suggest that FXYD2 can mediate basolateral extrusion of magnesium from cultured renal epithelial cells and provide new insights into the understanding of the possible physiological roles of FXYD2 wild-type and mutant proteins.</P>
]]></description>
<dc:creator><![CDATA[Sha, Q., Pearson, W., Burcea, L. C., Wigfall, D. A., Schlesinger, P. H., Nichols, C. G., Mercer, R. W.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00519.2007</dc:identifier>
<dc:title><![CDATA[Human FXYD2 G41R mutation responsible for renal hypomagnesemia behaves as an inward-rectifying cation channel]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F99</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F91</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F100?rss=1">
<title><![CDATA[Vasopressin regulates the renin-angiotensin-aldosterone system via V1a receptors in macula densa cells]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F100?rss=1</link>
<description><![CDATA[ 
<P>The neuropeptide hormone arginine-vasopressin (AVP) is well known to exert its antidiuretic effect via the vasopressin V2 receptor (V2R), whereas the role of the vasopressin V1a receptor (V1aR) in the kidney remains to be clarified. Previously, we reported decreased plasma volume and blood pressure in V1a receptor-deficient (V1aR<SUP>&ndash;/&ndash;</SUP>) mice (Koshimizu T, Nasa Y, Tanoue A, Oikawa R, Kawahara Y, Kiyono Y, Adachi T, Tanaka T, Kuwaki T, Mori T. <I>Proc Natl Acad Sci USA</I> 103: 7807&ndash;7812, 2006). In this study, we investigated the role of V1aR in urine concentration, renal function, and the renin-angiotensin system (RAS) using V1aR<SUP>&ndash;/&ndash;</SUP> mice. Urine volume of V1aR<SUP>&ndash;/&ndash;</SUP> mice was greater than that of wild-type mice, particularly when water was loaded, while the glomerular filtration rate (GFR), urinary NaCl excretion, AVP-dependent cAMP generation, V2R, and aquaporin 2 (AQP2) expression in the kidney were lower, indicating that the diminished GFR and V2R-AQP2 system led to impaired urinary concentration in V1aR<SUP>&ndash;/&ndash;</SUP> mice. Since the GFR and V2R-AQP2 system are regulated by RAS, we analyzed renin and angiotensin II in V1aR<SUP>&ndash;/&ndash;</SUP> mice and found that the plasma renin and angiotensin II were decreased. The expression of renin in granule cells was decreased in V1aR<SUP>&ndash;/&ndash;</SUP> mice, which led to a decreased level of plasma renin. In addition, the expression of renin stimulators such as neuronal nitric oxide synthase and cyclooxygenase-2 in macula densa (MD) cells, where V1aR was specifically expressed, was decreased in V1aR<SUP>&ndash;/&ndash;</SUP> mice. These data indicate that AVP regulates body fluid homeostasis and GFR via the V1aR in MD cells by activating RAS and subsequently the V2R-AQP2 system.</P>
]]></description>
<dc:creator><![CDATA[Aoyagi, T., Izumi, Y., Hiroyama, M., Matsuzaki, T., Yasuoka, Y., Sanbe, A., Miyazaki, H., Fujiwara, Y., Nakayama, Y., Kohda, Y., Yamauchi, J., Inoue, T., Kawahara, K., Saito, H., Tomita, K., Nonoguchi, H., Tanoue, A.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00088.2008</dc:identifier>
<dc:title><![CDATA[Vasopressin regulates the renin-angiotensin-aldosterone system via V1a receptors in macula densa cells]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F107</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F100</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F108?rss=1">
<title><![CDATA[Acute inhibition of the betaine transporter by ATP and adenosine in renal MDCK cells]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F108?rss=1</link>
<description><![CDATA[ 
<P>Extracellular ATP interacts with purinergic P2 receptors to regulate a range of physiological responses, including downregulation of transport activity in the nephron. ATP is released from cells by mechanical stimuli such as cell volume changes, and autocrine signaling by extracellular ATP could occur in renal medullary cells during diuresis. This was tested in Madin-Darby canine kidney (MDCK) cells, a model used frequently to study P1 and P2 receptor activity. ATP was released within 1 min after transfer from 500 to 300 mosmol/kgH<SUB>2</SUB>O medium. A 30-min incubation with ATP produced dose-dependent inhibition (0.01&ndash;0.10 mM) of the renal betaine/GABA transporter (BGT1) with little effect on other osmolyte transporters. Inhibition was reproduced by specific agonists for P2X (,&beta;-methylene-ATP) and P2Y (UTP) receptors. Adenosine, the final product of ATP hydrolysis, also inhibited BGT1 but not taurine transport. Inhibition by ATP and adenosine was blocked by pertussis toxin and A73122, suggesting involvement of inhibitory G protein and PLC in postreceptor signaling. Both ATP and adenosine (0.1 mM) produced rapid increases in intracellular Ca<SUP>2+</SUP>, due to the mobilization of intracellular Ca<SUP>2+</SUP> stores and Ca<SUP>2+</SUP> influx. Blocking these Ca<SUP>2+</SUP> increases with BAPTA-AM also blocked the action of ATP and adenosine on BGT1 transport. Finally, immunohistochemical studies indicated that inhibition of BGT1 transport may be due to endocytic accumulation of BGT1 proteins from the plasma membrane. We conclude that ATP and adenosine, through stimulation of PLC and intracellular Ca<SUP>2+</SUP>, may be rapidly acting regulators of BGT1 transport especially in response to a fall in extracellular osmolarity.</P>
]]></description>
<dc:creator><![CDATA[Kempson, S. A., Edwards, J. M., Osborn, A., Sturek, M.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00108.2008</dc:identifier>
<dc:title><![CDATA[Acute inhibition of the betaine transporter by ATP and adenosine in renal MDCK cells]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F117</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F108</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F118?rss=1">
<title><![CDATA[Mice overexpressing latent TGF-{beta}1 are protected against renal fibrosis in obstructive kidney disease]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F118?rss=1</link>
<description><![CDATA[ 
<P>Transforming growth factor (TGF)-&beta;1, once activated, binds to its receptors and mediates renal fibrosis via the downstream Smad signaling pathway. We reported here that mice overexpressing latent TGF-&beta;1 in keratinocytes were protected against renal fibrosis in a model of obstructive kidney disease. In normal mice, both transgenic (Tg) and wild-type (WT) mice had normal renal histology and function, despite a 10-fold increase in plasma latent TGF-&beta;1 in Tg mice. A severe renal fibrosis was developed in WT mice at 7 days after urinary obstruction. Unexpectedly, renal fibrosis was prevented in Tg mice, although levels of latent TGF-&beta;1 in both circulation and renal tissues remained high. Compared with the WT mice, quantitative real-time PCR showed that upregulation of renal -smooth muscle actin (SMA), collagen I, and collagen III mRNA was inhibited in Tg mice (60&ndash;70% reduced, all <I>P</I> &lt; 0.01). These were further confirmed by immunohistochemistry with a marked inhibition of tubulointerstitial accumulation of -SMA+ fibroblasts, collagen I, and collagen III matrix in Tg mice (all <I>P</I> &lt; 0.001). Further studies showed that inhibition of renal fibrosis in Tg mice was associated with a significant reduction in renal TGF-&beta;1 and CTGF (60% reduced, <I>P</I> &lt; 0.05), an increase in renal Smad7, a suppression of TSP-1 (a critical factor for TGF-&beta;1 activation), and an inhibition of Smad2/3 activation (all <I>P</I> &lt; 0.001). In conclusion, latent TGF-&beta; may play a protective role in renal fibrosis. Inhibition of renal TGF-&beta;1 expression and activation, thereby blocking the downstream TGF-&beta; signaling pathway, may be a critical mechanism by which latent TGF-&beta;1 protects against renal fibrosis.</P>
]]></description>
<dc:creator><![CDATA[Huang, X. R., Chung, A. C. K., Wang, X. J., Lai, K. N., Lan, H. Y.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00021.2008</dc:identifier>
<dc:title><![CDATA[Mice overexpressing latent TGF-{beta}1 are protected against renal fibrosis in obstructive kidney disease]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F127</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F118</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F128?rss=1">
<title><![CDATA[Sevoflurane protects against renal ischemia and reperfusion injury in mice via the transforming growth factor-{beta}1 pathway]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F128?rss=1</link>
<description><![CDATA[ 
<P>We previously demonstrated that several clinically utilized volatile anesthetics including sevoflurane protected against renal ischemia-reperfusion (IR) injury by reducing necrosis and inflammation in vivo. We also demonstrated that volatile anesthetics produced direct anti-necrotic and anti-inflammatory effects in cultured renal tubules via mechanisms involving the externalization of phosphatidylserine and subsequent release of transforming growth factor (TGF)-&beta;<SUB>1</SUB>. In this study, we tested the hypothesis that volatile anesthetic-mediated renal protection requires TGF-&beta;<SUB>1</SUB> and SMAD3 signaling in vivo. We subjected TGF-&beta;<SUB>1</SUB>+/+, TGF-&beta;<SUB>1</SUB>+/&ndash;, SMAD3+/+, or SMAD3&ndash;/&ndash; mice to renal IR under anesthesia with pentobarbital sodium or with sevoflurane. Although TGF-&beta;<SUB>1</SUB>+/+ and SMAD3+/+ mice were significantly protected against renal IR injury under sevoflurane anesthesia with reduced necrosis and inflammation, TGF-&beta;<SUB>1</SUB>+/&ndash; mice and SMAD3&ndash;/&ndash; mice were not protected against renal IR with sevoflurane. Furthermore, a neutralizing TGF-&beta;<SUB>1</SUB> antibody blocked renal protection with sevoflurane in TGF-&beta;<SUB>1</SUB>+/+ mice. Sevoflurane caused nuclear translocation of SMAD3 and reduced the TNF--induced nuclear translocation of NF-B in primary cultures of proximal tubules from TGF-&beta;<SUB>1</SUB>+/+ but not in TGF-&beta;<SUB>1</SUB>+/&ndash; mice. Finally, sevoflurane protected against necrosis induced with hydrogen peroxide in primary cultures of proximal tubules from TGF-&beta;<SUB>1</SUB>+/+ mice or SMAD3+/+ mice but not in proximal tubules from TGF-&beta;<SUB>1</SUB>+/&ndash; or SMAD3&ndash;/&ndash; mice. Therefore, we demonstrate in this study that sevoflurane-mediated renal protection in vivo requires the TGF-&beta;<SUB>1</SUB>-&gt;SMAD3 signaling pathway.</P>
]]></description>
<dc:creator><![CDATA[Lee, H. T., Chen, S. W. C., Doetschman, T. C., Deng, C., D'Agati, V. D., Kim, M.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00577.2007</dc:identifier>
<dc:title><![CDATA[Sevoflurane protects against renal ischemia and reperfusion injury in mice via the transforming growth factor-{beta}1 pathway]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F136</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F128</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F137?rss=1">
<title><![CDATA[Regression of glomerulosclerosis in subtotally nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combination]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F137?rss=1</link>
<description><![CDATA[ 
<P>Angiotensin II accelerates and renin-angiotensin system blockade halts progression; blockade with high doses even reverses established glomerulosclerosis. Aldosterone also accelerates progression of glomerulosclerosis, partially independently of angiotensin II. The purpose of this study was to assess the relative ability of an angiotensin receptor type 1 (AT<SUB>1</SUB>) blocker, a mineralocorticoid receptor blocker, and their combination to reverse glomerulosclerosis. Sprague-Dawley rats were subjected to subtotal renal ablation (SNX) or sham operation. Eight weeks after surgery, they were either euthanized or allocated to treatment with vehicle, losartan, spironolactone, their combination, or unspecific antihypertensive treatment (dihydralazine) for 4 wk. Renal morphology was evaluated by stereology in tissues obtained using pressure-controlled perfusion fixation. Systolic blood pressure was significantly higher in SNX compared with sham-operated animals and decreased in all treatment groups. Compared with <I>wk 8</I> after SNX, the glomerulosclerosis index (GSI) had increased further by <I>week 12</I> in the vehicle- and dihydralazine-treated groups but was significantly lowered in the SNX+losartan as well as in the SNX+losartan+spironolactone groups and had not progressed further in the SNX+spironolactone group. The study confirms the partial regression of established glomerulosclerosis in subtotally nephrectomized rats after high-dose AT<SUB>1</SUB> receptor blockade. Nonhyperkalemic doses of spironolactone prevented the increase but failed to decrease the GSI below the 8-wk level and preserved podocyte numbers. Combining the AT<SUB>1</SUB> blocker with mineralocorticoid receptor blockade failed to further increase the regression of glomerulosclerosis.</P>
]]></description>
<dc:creator><![CDATA[Piecha, G., Koleganova, N., Gross, M.-L., Geldyyev, A., Adamczak, M., Ritz, E.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00065.2008</dc:identifier>
<dc:title><![CDATA[Regression of glomerulosclerosis in subtotally nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combination]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F144</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F137</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F145?rss=1">
<title><![CDATA[Src regulates cell cycle protein expression and renal epithelial cell proliferation via PI3K/Akt signaling-dependent and -independent mechanisms]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F145?rss=1</link>
<description><![CDATA[ 
<P>Our recent studies showed that Src family kinases (SFKs) are important mediators of proliferation in renal proximal tubular cells (RPTC). In this study, we elucidate the signaling mechanisms that mediate SFK regulation of cell proliferation and cycle protein expression, and identify the SFK member responsible for these responses in a mouse RPTC line. Akt, a target of phosphoinositide-3-kinase (PI3K), and ERK1/2 were constitutively phosphorylated in RPTC cultured in the presence of serum. While treatment of cells with PP1, a specific SFK inhibitor, completely blocked phosphorylation of ERK1/2 and Akt, only inhibition of PI3K/Akt resulted in decreased RPTC proliferation. Incubation of cells with PP1 decreased cyclin D1 expression, decreased p27 and p57 phosphorylation, and increased p27 and p57 expression, two cyclin-dependent kinase inhibitors. Inhibition of the PI3K pathway decreased expression of cyclin D1 without altering expression of p27 and p57. In contrast, PP1 and PI3K inhibition had no effect on cyclin E and p21. Although RPTC expressed Src, Fyn, and Lyn, only siRNA-mediated knockdown of Src decreased RPTC proliferation, decreased cyclin D1 expression, and increased p27 and p57 expression. These data reveal that Src is a crucial mediator of RPTC proliferation and Src-mediated proliferation is associated with PI3K-dependent upregulation of cyclin D1 and PI3K-independent downregulation of p27 and p57.</P>
]]></description>
<dc:creator><![CDATA[Xing, J., Zhang, Z., Mao, H., Schnellmann, R. G., Zhuang, S.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00092.2008</dc:identifier>
<dc:title><![CDATA[Src regulates cell cycle protein expression and renal epithelial cell proliferation via PI3K/Akt signaling-dependent and -independent mechanisms]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F152</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F145</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F153?rss=1">
<title><![CDATA[TGF{beta}-induced RhoA activation and fibronectin production in mesangial cells require caveolae]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F153?rss=1</link>
<description><![CDATA[ 
<P>Glomerular sclerosis of diverse etiologies is characterized by mesangial matrix accumulation, with transforming growth factor-&beta; (TGF&beta;) an important pathogenic factor. The GTPase RhoA mediates TGF&beta;-induced matrix accumulation in some settings. Here we study the role of the membrane microdomain caveolae in TGF&beta;-induced RhoA activation and fibronectin upregulation in mesangial cells (MC). In primary rat MC, TGF&beta;1 time dependently increased RhoA and downstream Rho kinase activation. Rho pathway inhibition blocked TGF&beta;1-induced upregulation of fibronectin transcript and protein. TGF&beta;1-induced RhoA activation was prevented by disrupting caveolae with cholesterol depletion and rescued by cholesterol repletion. Compared with wild types, RhoA/Rho kinase activation was absent in MC lacking caveolae. Reexpression of caveolin-1 (and caveolae) restored these responses. Phosphorylation of caveolin-1 on Y14, effected by Src kinases, has been implicated in signaling responses. Overexpression of nonphosphorylatable caveolin-1 Y14A prevented TGF&beta;1-induced RhoA activation. TGF&beta;1 also activated Src, and its inhibition blocked RhoA activation. Furthermore, TGF&beta;1 led to association of RhoA and caveolin-1. This was prevented by Src or TGF&beta; receptor I inhibition, and by caveolin-1 Y14A overexpression. Last, fibronectin upregulation by TGF&beta;1 was blocked by Src inhibition, not seen in caveolin-1 knockout MC, and restored by caveolin-1 reexpression in the latter. TGF&beta;1-induced collagen I accumulation also required caveolae. TGF&beta;1-mediated Smad2/3 activation, however, did not require caveolae. We conclude that RhoA/Rho kinase mediates TGF&beta;-induced fibronectin upregulation. This requires caveolae and caveolin-1 interaction with RhoA. Interference with caveolin/caveolae or RhoA signaling thus represents a potential target for the treatment of fibrotic renal disease.</P>
]]></description>
<dc:creator><![CDATA[Peng, F., Zhang, B., Wu, D., Ingram, A. J., Gao, B., Krepinsky, J. C.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00419.2007</dc:identifier>
<dc:title><![CDATA[TGF{beta}-induced RhoA activation and fibronectin production in mesangial cells require caveolae]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F164</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F153</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F165?rss=1">
<title><![CDATA[Kidney-specific expression of human organic cation transporter 2 (OCT2/SLC22A2) is regulated by DNA methylation]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F165?rss=1</link>
<description><![CDATA[ 
<P>Human organic cation transporter 2 (OCT2/SLC22A2), which is specifically expressed in the kidney, plays critical roles in the renal secretion of cationic compounds. Tissue expression and membrane localization of OCT2 are closely related to the tissue distribution, pharmacological effects, and/or adverse effects of its substrate drugs. However, the molecular mechanisms underlying the kidney-specific expression of OCT2 have not been elucidated. In the present study, therefore, we examined the contribution of DNA methylation of the promoter region for the <I>OCT2</I> gene to its tissue-specific expression using human tissue samples. In vivo methylation status of the proximal promoter region of OCT2 and that of OCT1, a liver-specific organic cation transporter, were investigated by bisulfite sequencing using human genomic DNA extracted from the kidney and liver. All CpG sites in the OCT2 proximal promoter were hypermethylated in the liver, while hypomethylated in the kidney. On the other hand, the promoter region of OCT1 was hypermethylated in both the kidney and liver. The level of methylation of the OCT2 promoter was especially low at the CpG site in the E-box, the binding site of the basal transcription factor upstream stimulating factor (USF) 1. In vitro methylation of the OCT2 proximal promoter dramatically reduced the transcriptional activity, and an electrophoretic mobility shift assay showed that methylation at the E-box inhibited the binding of USF1. These results indicate that kidney-specific expression of human OCT2 is regulated by methylation of the proximal promoter region, interfering with the transactivation by USF1.</P>
]]></description>
<dc:creator><![CDATA[Aoki, M., Terada, T., Kajiwara, M., Ogasawara, K., Ikai, I., Ogawa, O., Katsura, T., Inui, K.-i.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.90257.2008</dc:identifier>
<dc:title><![CDATA[Kidney-specific expression of human organic cation transporter 2 (OCT2/SLC22A2) is regulated by DNA methylation]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F170</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F165</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F171?rss=1">
<title><![CDATA[Potassium channel contributions to afferent arteriolar tone in normal and diabetic rat kidney]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F171?rss=1</link>
<description><![CDATA[ 
<P>We previously reported an enhanced tonic dilator impact of ATP-sensitive K<SUP>+</SUP> channels in afferent arterioles of rats with streptozotocin (STZ)-induced diabetes. The present study explored the hypothesis that other types of K<SUP>+</SUP> channel also contribute to afferent arteriolar dilation in STZ rats. The in vitro blood-perfused juxtamedullary nephron technique was utilized to quantify afferent arteriolar lumen diameter responses to K<SUP>+</SUP> channel blockers: 0.1&ndash;3.0 mM 4-aminopyridine (4-AP; K<SUB>V</SUB> channels), 10&ndash;100 &micro;M barium (K<SUB>IR</SUB> channels), 1&ndash;100 nM tertiapin-Q (TPQ; Kir1.1 and Kir3.x subfamilies of K<SUB>IR</SUB> channels), 100 nM apamin (SK<SUB>Ca</SUB> channels), and 1 mM tetraethylammonium (TEA; BK<SUB>Ca</SUB> channels). In kidneys from normal rats, 4-AP, TEA, and Ba<SUP>2+</SUP> reduced afferent diameter by 23 &plusmn; 3, 8 &plusmn; 4, and 18 &plusmn; 2%, respectively, at the highest concentrations employed. Neither TPQ nor apamin significantly altered afferent diameter. In arterioles from STZ rats, a constrictor response to TPQ (22 &plusmn; 4% decrease in diameter) emerged, and the response to Ba<SUP>2+</SUP> was exaggerated (28 &plusmn; 5% decrease in diameter). Responses to the other K<SUP>+</SUP> channel blockers were similar to those observed in normal rats. Moreover, exposure to either TPQ or Ba<SUP>2+</SUP> reversed the afferent arteriolar dilation characteristic of STZ rats. Acute surgical papillectomy did not alter the response to TPQ in arterioles from normal or STZ rats. We conclude that <I>1</I>) K<SUB>V</SUB>, K<SUB>IR</SUB>, and BK<SUB>Ca</SUB> channels tonically influence normal afferent arteriolar tone, <I>2</I>) K<SUB>IR</SUB> channels (including Kir1.1 and/or Kir3.x) contribute to the afferent arteriolar dilation during diabetes, and <I>3</I>) the dilator impact of Kir1.1/Kir3.x channels during diabetes is independent of solute delivery to the macula densa.</P>
]]></description>
<dc:creator><![CDATA[Troncoso Brindeiro, C. M., Fallet, R. W., Lane, P. H., Carmines, P. K.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00563.2007</dc:identifier>
<dc:title><![CDATA[Potassium channel contributions to afferent arteriolar tone in normal and diabetic rat kidney]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F178</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F171</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F179?rss=1">
<title><![CDATA[A p38 mitogen-activated protein kinase inhibitor protects against renal damage in a non-heart-beating donor model]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F179?rss=1</link>
<description><![CDATA[ 
<P>Ischemia-reperfusion injury is one of the central nonimmunologic processes involved in renal allograft dysfunction. Kidneys from non-heart beating donors (NHBD) exhibit higher rates of delayed graft function (DGF) than those from other donors. Primary nonfunction and DGF are the main barriers to the use of kidneys from NHBD. Using a pig model of NHBD transplantation, we studied the effect of FR167653 (a p38 MAP kinase inhibitor) on the recovery and reparation of kidneys exposed to both warm (WI: 1 h) and cold ischemia (24 h). Our results demonstrate that the addition of FR167653 increases the kinetics of proximal tubule cell regeneration after 60 min of WI. Hypoxia-inducible factor and vascular endothelial growth factor expression was also more important in FR167653-treated kidneys compared with those in nontreated groups. Also, expression of peripheral-type benzodiazepine receptor, involved in tissue repair, was increased in the FR167653-treated groups. At 3 mo, the protective effects of FR167653 were accompanied by a reduction of long-term inflammation process and tubulointerstitial fibrosis development associated with a limitation of ischemia-induced remodeling. This study suggests that such treatment may be useful in protocols aimed at improving the quality of renal transplants from NHBD. In addition, the beneficial role of FR167653 in limiting early injury is associated with secondary reduction in development of tubular atrophy and interstitial fibrosis which are together the hallmark of failing renal transplants. The more efficient effect was observed when FR167653 was added in combination before WI, during cold storage and reperfusion.</P>
]]></description>
<dc:creator><![CDATA[Doucet, C., Milin, S., Favreau, F., Desurmont, T., Manguy, E., Hebrard, W., Yamamoto, Y., Mauco, G., Eugene, M., Papadopoulos, V., Hauet, T., Goujon, J. M.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00252.2007</dc:identifier>
<dc:title><![CDATA[A p38 mitogen-activated protein kinase inhibitor protects against renal damage in a non-heart-beating donor model]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F191</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F179</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F192?rss=1">
<title><![CDATA[Roles of basolateral solute uptake via NKCC1 and of myosin II in vasopressin-induced cell swelling in inner medullary collecting duct]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F192?rss=1</link>
<description><![CDATA[ 
<P>Collecting duct cells swell when exposed to arginine vasopressin (AVP) in the presence of a transepithelial osmolality gradient. We investigated the mechanisms of AVP-induced cell swelling in isolated, perfused rat inner medullary collecting ducts (IMCDs) using quantitative video microscopy and fluorescence-based measurements of transepithelial water transport. We tested the roles of transepithelial water flow, basolateral solute entry, and the cytoskeleton (actomyosin). When a transepithelial osmolality gradient was imposed by addition of NaCl to the bath, AVP significantly increased both water flux and cell height. When the osmolality gradient was imposed by addition of mannitol, AVP increased water flux but not cell height, suggesting that AVP-induced cell swelling requires a NaCl gradient and is not merely dependent on the associated water flux. Bumetanide (Na-K-2Cl cotransporter inhibitor) added to the bath markedly diminished the AVP-induced cell height increase. AVP-induced cell swelling was absent in IMCDs from NKCC1-knockout mice. In rat IMCDs, replacement of Na, K, or Cl in the peritubular bath caused significant cell shrinkage, consistent with a basolateral solute transport pathway dependent on all three ions. Immunocytochemistry using an antibody to NKCC1 confirmed basolateral expression in IMCD cells. The conventional nonmuscle myosin II inhibitor blebbistatin also diminished the AVP-induced cell height increase and cell shape change, consistent with a role for the actin cytoskeleton and myosin II. We conclude that the AVP-induced cell height increase is dependent on basolateral solute uptake via NKCC1 and changes in actin organization via myosin II, but is not dependent specifically on increased apical water entry.</P>
]]></description>
<dc:creator><![CDATA[Chou, C.-L., Yu, M.-J., Kassai, E. M., Morris, R. G., Hoffert, J. D., Wall, S. M., Knepper, M. A.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00011.2008</dc:identifier>
<dc:title><![CDATA[Roles of basolateral solute uptake via NKCC1 and of myosin II in vasopressin-induced cell swelling in inner medullary collecting duct]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F201</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F192</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F202?rss=1">
<title><![CDATA[HSP72 attenuates renal tubular cell apoptosis and interstitial fibrosis in obstructive nephropathy]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F202?rss=1</link>
<description><![CDATA[ 
<P>Although heat shock protein 72 kDa (HSP72) protects tubular epithelium from a variety of acute insults, its role in chronic renal injury and fibrosis is poorly characterized. In this study, we tested the hypothesis that HSP72 reduces apoptosis and epithelial-to-mesenchymal transition (EMT), important contributors to tubular cell injury in vitro and in vivo. In rats, orally administered geranylgeranylacetone (GGA), an agent that selectively induces HSP72, markedly reduced both apoptosis and cell proliferation in tubular epithelium and decreased both interstitial fibroblast accumulation and collagen I deposition after unilateral ureteric obstruction, a model of chronic renal tubulointerstitial fibrosis and dysfunction. In cultured renal NRK52E cells, exposure to TGF-&beta;1 induced EMT and apoptosis, major causes of renal fibrosis and tubular atrophy, respectively. Exposure to a pan-caspase inhibitor (ZVAD-FMK) prevented TGF-&beta;1-induced apoptosis but did not reduce EMT. In contrast, selective HSP72 expression in vitro inhibited EMT caused by TGF-&beta;1 as indicated by preserving the E-cadherin expression level and -smooth muscle actin induction. Small interfering RNA directed against HSP72 blocked the cytoprotective effects of HSP72 overexpression on EMT in TGF-&beta;1-exposed cells. Taken together, our data indicate that HSP72 ameliorates renal tubulointerstitial fibrosis in obstructive nephropathy by inhibiting both renal tubular epithelial cell apoptosis and EMT.</P>
]]></description>
<dc:creator><![CDATA[Mao, H., Li, Z., Zhou, Y., Li, Z., Zhuang, S., An, X., Zhang, B., Chen, W., Nie, J., Wang, Z., Borkan, S. C., Wang, Y., Yu, X.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00468.2007</dc:identifier>
<dc:title><![CDATA[HSP72 attenuates renal tubular cell apoptosis and interstitial fibrosis in obstructive nephropathy]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F214</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F202</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F215?rss=1">
<title><![CDATA[Protein kinase B/Akt activity is involved in renal TGF-{beta}1-driven epithelial-mesenchymal transition in vitro and in vivo]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F215?rss=1</link>
<description><![CDATA[ 
<P>The molecular pathogenesis of diabetic nephropathy (DN), the leading cause of end-stage renal disease worldwide, is complex and not fully understood. Transforming growth factor-&beta; (TGF-&beta;1) plays a critical role in many fibrotic disorders, including DN. In this study, we report protein kinase B (PKB/Akt) activation as a downstream event contributing to the pathophysiology of DN. We investigated the potential of PKB/Akt to mediate the profibrotic bioactions of TGF-&beta;1 in kidney. Treatment of normal rat kidney epithelial cells (NRK52E) with TGF-&beta;1 resulted in activation of phosphatidylinositol 3-kinase (PI3K) and PKB/Akt as evidenced by increased Ser<SUP>473</SUP> phosphorylation and GSK-3&beta; phosphorylation. TGF-&beta;1 also stimulated increased Smad3 phosphorylation in these cells, a response that was insensitive to inhibition of PI3K or PKB/Akt. NRK52E cells displayed a loss of zona occludins 1 and E-cadherin and a gain in vimentin and -smooth muscle actin expression, consistent with the fibrotic actions of TGF-&beta;1. These effects were blocked with inhibitors of PI3K and PKB/Akt. Furthermore, overexpression of PTEN, the lipid phosphatase regulator of PKB/Akt activation, inhibited TGF-&beta;1-induced PKB/Akt activation. Interestingly, in the Goto-Kakizaki rat model of type 2 diabetes, we also detected increased phosphorylation of PKB/Akt and its downstream target, GSK-3&beta;, in the tubules, relative to that in control Wistar rats. Elevated Smad3 phosphorylation was also detected in kidney extracts from Goto-Kakizaki rats with chronic diabetes. Together, these data suggest that TGF-&beta;1-mediated PKB/Akt activation may be important in renal fibrosis during diabetic nephropathy.</P>
]]></description>
<dc:creator><![CDATA[Kattla, J. J., Carew, R. M., Heljic, M., Godson, C., Brazil, D. P.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00548.2007</dc:identifier>
<dc:title><![CDATA[Protein kinase B/Akt activity is involved in renal TGF-{beta}1-driven epithelial-mesenchymal transition in vitro and in vivo]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F225</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F215</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F226?rss=1">
<title><![CDATA[Indoleamine 2,3-dioxygenase expression promotes renal ischemia-reperfusion injury]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F226?rss=1</link>
<description><![CDATA[ 
<P>Indoleamine 2,3-dioxygenase (IDO) catabolizes tryptophan to <I>N</I>-formyl kynurenine and has a proapoptotic role in renal tubular epithelial cells (TEC) in response to IFN- and TNF- in vitro. TEC produce abundant amounts of IDO in vitro in response to inflammation but a pathological role for IDO in renal injury remains unknown. We investigated the role of IDO in a mouse model of renal ischemia-reperfusion injury (IRI). IRI was induced by clamping the renal pedicle of C57BL/6 mice for 45 min at 32&deg;C. Here, we demonstrate upregulation of IDO in renal tissue at 2 h after reperfusion which reached maximal levels at 24 h. Inhibition of IDO following IRI prevented the increase in serum creatinine observed in vehicle-treated mice (86.4 &plusmn; 25 &micro;mol/l, <I>n</I> = 11) compared with mice treated with 1-methyl-<SCP>d</SCP>-tryptophan, a specific inhibitor of IDO (33.7 &plusmn; 8.7 &micro;mol/l, <I>n</I> = 10, <I>P</I> = 0.031). The role of IDO in renal IRI was further supported by results in IDO-KO mice which maintained normal serum creatinine levels (32.5 &plusmn; 2.0 &micro;mol/l, <I>n</I> = 6) following IRI compared with wild-type mice (123 &plusmn; 30 &micro;mol/l, <I>n</I> = 9, <I>P</I> = 0.008). Our data suggest that attenuation of IDO expression within the kidney may represent a novel strategy to reduce renal injury as a result of ischemia reperfusion.</P>
]]></description>
<dc:creator><![CDATA[Mohib, K., Wang, S., Guan, Q., Mellor, A. L., Sun, H., Du, C., Jevnikar, A. M.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00567.2007</dc:identifier>
<dc:title><![CDATA[Indoleamine 2,3-dioxygenase expression promotes renal ischemia-reperfusion injury]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F234</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F226</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F235?rss=1">
<title><![CDATA[Nephrin binds to the COOH terminus of a large-conductance Ca2+-activated K+ channel isoform and regulates its expression on the cell surface]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F235?rss=1</link>
<description><![CDATA[ 
<P>We carried out a yeast two-hybrid screen to identify proteins that interact with large-conductance Ca<SUP>2+</SUP>-activated K<SUP>+</SUP> (BK<SUB>Ca</SUB>) channels encoded by the <I>Slo1</I> gene. Nephrin, an essential adhesion and scaffolding molecule expressed in podocytes, emerged in this screen. The Slo1-nephrin interaction was confirmed by coimmunoprecipitation from the brain and kidney, from HEK-293T cells expressing both proteins, and by glutathione <I>S</I>-transferase pull-down assays. We detected nephrin binding to the Slo1<SUB>VEDEC</SUB> splice variant, which is typically retained in intracellular stores, and to the &beta;4-subunit. However, we did not detect significant binding of nephrin to the Slo1<SUB>QEERL</SUB> or Slo1<SUB>EMVYR</SUB> splice variants. Coexpression of nephrin with Slo1<SUB>VEDEC</SUB> increased expression of functional BK<SUB>Ca</SUB> channels on the surface of HEK-293T cells but did not affect steady-state surface expression of the other COOH-terminal Slo1 variants. Nephrin did not affect the kinetics or voltage dependence of channel activation in HEK-293T cells expressing Slo1. Stimulation of Slo1<SUB>VEDEC</SUB> surface expression in HEK-293T cells was also observed by coexpressing a small construct encoding only the distal COOH-terminal domains of nephrin that interact with Slo1. Reduction of endogenous nephrin expression by application of small interfering RNA to differentiated cells of an immortalized podocyte cell line markedly reduced the steady-state surface expression of Slo1 as assessed by electrophysiology and cell-surface biotinylation assays. Nephrin therefore plays a role in organizing the surface expression of ion channel proteins in podocytes and may play a role in outside-in signaling to allow podocytes to adapt to mechanical or neurohumoral stimuli originating in neighboring cells.</P>
]]></description>
<dc:creator><![CDATA[Kim, E. Y., Choi, K.-J., Dryer, S. E.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00140.2008</dc:identifier>
<dc:title><![CDATA[Nephrin binds to the COOH terminus of a large-conductance Ca2+-activated K+ channel isoform and regulates its expression on the cell surface]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F246</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F235</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F247?rss=1">
<title><![CDATA[Adaptive responses of renal organic anion transporter 3 (OAT3) during cholestasis]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F247?rss=1</link>
<description><![CDATA[ 
<P>During cholestasis, bile acids are mainly excreted into the urine, but adaptive renal responses to cholestasis, especially molecular mechanisms for renal secretion of bile acids, have not been well understood. Organic anion transporters (OAT1 and OAT3) are responsible for membrane transport of anionic compounds at the renal basolateral membranes. In the present study, we investigated the pathophysiological roles of OAT1 and OAT3 in terms of renal handling of bile acids. The Eisai hyperbilirubinemic rats (EHBR), mutant rats without multidrug resistance-associated protein 2, showed higher serum and urinary concentrations of bile acids, compared with Sprague-Dawley (SD) rats (wild type). The protein expression level of rat OAT3 was significantly increased in EHBR compared with SD rats, whereas the expression of rat OAT1 was unchanged. The transport activities of rat and human OAT3, but not OAT1, were markedly inhibited by various bile acids such as chenodeoxycholic acid and cholic acid. Cholic acid, glycocholic acid, and taurocholic acid, which mainly increased during cholestasis, are transported by OAT3. The plasma concentration of &beta;-lactam antibiotic cefotiam, a specific substrate for OAT3, was more increased in EHBR than in SD rats despite upregulation of OAT3 protein. This may be due to the competitive inhibition of cefotiam transport by bile acids via OAT3. In conclusion, the present study clearly demonstrated that OAT3 is responsible for renal secretion of bile acids during cholestasis and that the pharmacokinetic profile of OAT3 substrates may be affected by cholestasis.</P>
]]></description>
<dc:creator><![CDATA[Chen, J., Terada, T., Ogasawara, K., Katsura, T., Inui, K.-i.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00139.2008</dc:identifier>
<dc:title><![CDATA[Adaptive responses of renal organic anion transporter 3 (OAT3) during cholestasis]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F252</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F247</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F253?rss=1">
<title><![CDATA[Roles of PINCH-2 in regulation of glomerular cell shape change and fibronectin matrix deposition]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F253?rss=1</link>
<description><![CDATA[ 
<P>The PINCH-1-integrin-linked kinase (ILK)--parvin (PIP) complex plays important roles in the regulation of glomerular cell behavior, including podocyte shape change, apoptosis, and mesangial fibronectin matrix deposition. In this study, we show that PINCH-2, a protein that is structurally related to PINCH-1 but encoded by a different gene, is coexpressed with PINCH-1 in podocytes. Treatment of podocytes with transforming growth factor (TGF)-&beta;1 elevated the level of PINCH-2, resulting in increased association of PINCH-2 with ILK and -parvin and concomitant displacement of PINCH-1 from the PIP complex. To gain insights into the functional consequences of elevated PINCH-2 expression, we overexpressed PINCH-2 in podocytes by infection with an adenovirus encoding PINCH-2. Overexpression of PINCH-2 resulted in displacement of PINCH-1 from the PIP complex and compromised podocyte spreading. The PINCH-2-mediated displacement of PINCH-1, however, did not prompt apoptosis. Interestingly, the effect of PINCH-2 on podocyte spreading depends on differentiation status, as overexpression of PINCH-2 in podocytes that were not fully differentiated did not alter cell spreading. Finally, we show that overexpression of PINCH-2 in mesangial cells resulted in displacement of PINCH-1 from the PIP complex but impaired neither mesangial cell spreading nor fibronectin matrix deposition. These studies suggest that PINCH-2 can substitute for PINCH-1 in at least certain processes in glomerular cells (e.g., podocyte survival signaling and mesangial fibronectin matrix deposition), albeit that an aberrantly high level of PINCH-2 may contribute to TGF-&beta;1-induced alteration in podocyte shape modulation.</P>
]]></description>
<dc:creator><![CDATA[Shi, X., Qu, H., Kretzler, M., Wu, C.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00070.2008</dc:identifier>
<dc:title><![CDATA[Roles of PINCH-2 in regulation of glomerular cell shape change and fibronectin matrix deposition]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F263</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F253</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F264?rss=1">
<title><![CDATA[Effect of duloxetine, a norepinephrine and serotonin reuptake inhibitor, on sneeze-induced urethral continence reflex in rats]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F264?rss=1</link>
<description><![CDATA[ 
<P>We investigated the effect of duloxetine, a norepinephrine (NE) and serotonin (5-HT) reuptake inhibitor, on the neurally evoked urethral continence reflex induced by sneezing in rats. To clarify the role of noradrenergic and serotonergic mechanisms in preventing stress urinary incontinence (SUI) during sneezing, we examined the effect of duloxetine followed by intrathecal (it) methiothepin maleate (5-HT receptor and <SUB>1</SUB>-adrenoceptor antagonist) or terazosin or idazoxan (selective <SUB>1</SUB>- and <SUB>2</SUB>-adrenoceptor antagonists, respectively). Amplitude of urethral pressure responses during sneezing (A-URS), urethral baseline pressure (UBP) at the midurethra, and sneeze-induced leak point pressure (S-LPP) were measured in normal adult female rats and rats with SUI induced by vaginal distension (VD). In normal and VD rats, intravenous application of duloxetine (1 mg/kg) increased A-URS by 35% and 34% and UBP by 21% and 34%, respectively. Sneezing-induced fluid leakage from the urethral orifice was observed in VD rats but not in normal rats. S-LPP was increased from 39.1 to 92.2 cmH<SUB>2</SUB>O by intravenous duloxetine in incontinent VD rats. Duloxetine-mediated enhancement of A-URS was inhibited by terazosin but not methiothepin maleate (it). In addition, simultaneous intrathecal application of methiothepin and terazosin induced a reduction in A-URS during sneezing, which was not increased by intravenous duloxetine. However, the reduced A-URS after intrathecal application of methiothepin and terazosin returned to the control level when duloxetine (iv) was applied after intrathecal idazoxan administration. These results indicate that duloxetine can prevent SUI by facilitating noradrenergic and serotonergic systems in the spinal cord to enhance the sneeze-induced active urethral closure mechanism.</P>
]]></description>
<dc:creator><![CDATA[Miyazato, M., Kaiho, Y., Kamo, I., Chancellor, M. B., Sugaya, K., de Groat, W. C., Yoshimura, N.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.90241.2008</dc:identifier>
<dc:title><![CDATA[Effect of duloxetine, a norepinephrine and serotonin reuptake inhibitor, on sneeze-induced urethral continence reflex in rats]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F271</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F264</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F272?rss=1">
<title><![CDATA[Effects of amiloride, benzamil, and alterations in extracellular Na+ on the rat afferent arteriole and its myogenic response]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F272?rss=1</link>
<description><![CDATA[ 
<P>Recent studies have implicated epithelial Na<SUP>+</SUP> channels (ENaC) in myogenic signaling. The present study was undertaken to determine if ENaC and/or Na<SUP>+</SUP> entry are involved in the myogenic response of the rat afferent arteriole. Myogenic responses were assessed in the in vitro hydronephrotic kidney model. ENaC expression and membrane potential responses were evaluated with afferent arterioles isolated from normal rat kidneys. Our findings do not support a role of ENaC, in that ENaC channel blockers did not reduce myogenic responses and ENaC expression could not be demonstrated in this vessel. Reducing extracellular Na<SUP>+</SUP> concentration ([Na<SUP>+</SUP>]<SUB>o</SUB>; 100 mmol/l) did not attenuate myogenic responses, and amiloride had no effect on membrane potential. Benzamil, an inhibitor of ENaC that also blocks Na<SUP>+</SUP>/Ca<SUP>2+</SUP> exchange (NCX), potentiated myogenic vasoconstriction. Benzamil and low [Na<SUP>+</SUP>]<SUB>o</SUB> elicited vasoconstriction; however, these responses were attenuated by diltiazem and were associated with significant membrane depolarization, suggesting a contribution of mechanisms other than a reduction in NCX. Na<SUP>+</SUP> repletion induced a vasodilation in pressurized afferent arterioles preequilibrated in low [Na<SUP>+</SUP>]<SUB>o</SUB>, a hallmark of NCX, and this response was reduced by 10 &micro;mol/l benzamil. The dilation was eliminated, however, by a combination of benzamil plus ouabain, suggesting an involvement of the electrogenic Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase. In concert, these findings refute the premise that ENaC plays a significant role in the rat afferent arteriole and instead suggest that reducing [Na<SUP>+</SUP>]<SUB>o</SUB> and/or Na<SUP>+</SUP> entry is coupled to membrane depolarization. The mechanisms underlying these unexpected and paradoxical effects of Na<SUP>+</SUP> are not resolved at the present time.</P>
]]></description>
<dc:creator><![CDATA[Wang, X., Takeya, K., Aaronson, P. I., Loutzenhiser, K., Loutzenhiser, R.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00200.2007</dc:identifier>
<dc:title><![CDATA[Effects of amiloride, benzamil, and alterations in extracellular Na+ on the rat afferent arteriole and its myogenic response]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F282</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F272</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F283?rss=1">
<title><![CDATA[Costimulation with angiotensin II and interleukin 6 augments angiotensinogen expression in cultured human renal proximal tubular cells]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F283?rss=1</link>
<description><![CDATA[ 
<P>Augmented intrarenal ANG II stimulates IL-6, which contributes to renal injury. The expression of intrarenal angiotensinogen (AGT) is enhanced by increased intrarenal ANG II in human renin/human AGT double transgenic mice. ANG II also augments AGT expression in hepatocytes and cardiac myocytes. However, the mechanisms underlying AGT augmentation by ANG II and the contribution of IL-6 to this system are poorly understood. This study was performed in human renal proximal tubular epithelial cells (HRPTECs) to test the hypothesis that IL-6 contributes to the upregulation of AGT expression by ANG II. Human kidney-2 (HK-2) cells, immortalized HRPTECs, were incubated with 10<SUP>&ndash;7</SUP> M ANG II and/or 10 ng/ml IL-6 for up to 24 h. AGT mRNA and protein expressions were measured by real-time RT-PCR and ELISA, respectively. The activities of NF-B and STAT3 were evaluated by Western blotting and EMSA. Stimulation with either ANG II or IL-6 did not significantly alter AGT mRNA or protein expression. In contrast, costimulation with ANG II and IL-6 significantly increased AGT mRNA and protein expressions (1.26 &plusmn; 0.10 and 1.16 &plusmn; 0.13 over control, respectively). Olmesartan, an ANG II type 1 receptor blocker, and an IL-6 receptor antibody individually inhibited this synergistic effect. NF-B was also activated by costimulation with ANG II and IL-6. Phosphorylation and activity of STAT3 were increased by stimulation with IL-6 alone and by costimulation. The present study indicates that IL-6 plays an important role in ANG II-mediated augmentation of AGT expression in human renal proximal tubular cells.</P>
]]></description>
<dc:creator><![CDATA[Satou, R., Gonzalez-Villalobos, R. A., Miyata, K., Ohashi, N., Katsurada, A., Navar, L. G., Kobori, H.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00047.2008</dc:identifier>
<dc:title><![CDATA[Costimulation with angiotensin II and interleukin 6 augments angiotensinogen expression in cultured human renal proximal tubular cells]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F289</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F283</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F290?rss=1">
<title><![CDATA[The phosphorylation state of serine 256 is dominant over that of serine 261 in the regulation of AQP2 trafficking in renal epithelial cells]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F290?rss=1</link>
<description><![CDATA[ 
<P>Phosphorylation of serine 256 (S256) plays a critical role in vasopressin (VP)-mediated membrane accumulation of aquaporin-2 (AQP2). Recently, phosphorylation of serine 261 was also reported, raising the possibility that it has a role in AQP2 trafficking. We addressed this issue using transfected LLC-PK<SUB>1</SUB> cells that express point mutations of AQP2 S261 and S256, mimicking the phosphorylated (S to D) or dephosphorylated (S to A) states of these residues. Both AQP2 (S261A) and AQP2 (S261D) were located in the perinuclear cytoplasm without stimulation but, like wild-type AQP2, they both accumulated on the plasma membrane after 20-min exposure to VP or forskolin. Following membrane accumulation, S261A, S261D, and wild-type AQP2 reinternalization was complete over a similar time frame, between 30 and 60 min after VP washout. Using various combinations of point mutations, we showed that the phosphorylation state of S256 is dominant with respect to AQP2 behavior; AQP2 membrane accumulation and internalization were not detectably affected by the phosphorylation state of S261. Finally, blocking AQP2 endocytosis by methyl-&beta;-cyclodextrin caused membrane accumulation of AQP2 in cells expressing either a single S-A mutation or double mutations of S256 and S261, although as previously reported, the S256D mutation was always present at the cell surface. This suggests that constitutive recycling of AQP2 was not modified by the phosphorylation state of S261. Together, our data indicate that the phosphorylation state of AQP2 at S261 does not detectably affect regulated or constitutive trafficking of AQP2. The potential role of S261 phosphorylation/dephosphorylation in vasopressin action remains to be determined.</P>
]]></description>
<dc:creator><![CDATA[Lu, H. J., Matsuzaki, T., Bouley, R., Hasler, U., Qin, Q.-H., Brown, D.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00072.2008</dc:identifier>
<dc:title><![CDATA[The phosphorylation state of serine 256 is dominant over that of serine 261 in the regulation of AQP2 trafficking in renal epithelial cells]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F294</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F290</prism:startingPage>
<prism:section>REPORTS</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F295?rss=1">
<title><![CDATA[Phosphorylation of UT-A1 urea transporter at serines 486 and 499 is important for vasopressin-regulated activity and membrane accumulation]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F295?rss=1</link>
<description><![CDATA[ 
<P>The UT-A1 urea transporter plays an important role in the urine concentrating mechanism. Vasopressin (or cAMP) increases urea permeability in perfused terminal inner medullary collecting ducts and increases the abundance of phosphorylated UT-A1, suggesting regulation by phosphorylation. We performed a phosphopeptide analysis that strongly suggested that a PKA consensus site(s) in the central loop region of UT-A1 was/were phosphorylated. Serine 486 was most strongly identified, with other potential sites at serine 499 and threonine 524. Phosphomutation constructs of each residue were made and transiently transfected into LLC-PK<SUB>1</SUB> cells to assay for UT-A1 phosphorylation. The basal level of UT-A1 phosphorylation was unaltered by mutation of these sites. We injected oocytes, assayed [<SUP>14</SUP>C]urea flux, and determined that mutation of these sites did not alter basal urea transport activity. Next, we tested the effect of stimulating cAMP production with forskolin. Forskolin increased wild-type UT-A1 and T524A phosphorylation in LLC-PK<SUB>1</SUB> cells and increased urea flux in oocytes. In contrast, the S486A and S499A mutants demonstrated loss of forskolin-stimulated UT-A1 phosphorylation and reduced urea flux. In LLC-PK<SUB>1</SUB> cells, we assessed biotinylated UT-A1. Wild-type UT-A1, S486A, and S499A accumulated in the membrane in response to forskolin. However, in the S486A/S499A double mutant, forskolin-stimulated UT-A1 membrane accumulation and urea flux were totally blocked. We conclude that the phosphorylation of UT-A1 on both serines 486 and 499 is important for activity and that this phosphorylation may be involved in UT-A1 membrane accumulation.</P>
]]></description>
<dc:creator><![CDATA[Blount, M. A., Mistry, A. C., Frohlich, O., Price, S. R., Chen, G., Sands, J. M., Klein, J. D.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00102.2008</dc:identifier>
<dc:title><![CDATA[Phosphorylation of UT-A1 urea transporter at serines 486 and 499 is important for vasopressin-regulated activity and membrane accumulation]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F299</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F295</prism:startingPage>
<prism:section>REPORTS</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F300?rss=1">
<title><![CDATA[A novel method of ligand peptidomics to identify peptide ligands binding to AQP2-expressing plasma membranes and intracellular vesicles of rat kidney]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F300?rss=1</link>
<description><![CDATA[ 
<P>Aquaporin-2 (AQP2), the vasopressin-regulated water channel in collecting duct principal cells, plays a key role in the regulation of body water balance. We aimed to isolate high-affinity peptide ligands that bind to immunoisolated AQP2-expressing plasma membrane (PM) or intracellular vesicle (ICV) preparations from rat kidney by the in vitro phage display technique. Immunoblotting revealed that AQP2 was exclusively expressed in the immunoisolated AQP2 membrane fractions (PM and ICV), compared with the nonimmunoisolated or preimmune IgG pulldown rat kidney samples. Moreover, AQP1 or H<SUP>+</SUP>-ATPase (B1 subunit) expression was minimal in the immunoisolated AQP2 membrane fractions, indicating the specificity of AQP2 membrane isolation. A phage peptide library based on T7 415-1b phage vector displaying CX<SUB>7</SUB>C was constructed. After three rounds of biopanning, seven phage clones of high frequency were selected, which showed high affinity to the AQP2-containing PM or ICV fractions compared with a nonrecombinant T7 insertless phage clone. In contrast, these phage clones showed lower affinity to H<SUP>+</SUP>-ATPase-containing fractions. Fluorescein-conjugated peptide labeling was associated with intracellular compartment and PM of primary cultured inner medullary collecting duct cells, relative to absent or very weak labeling with fluorescein-conjugated control peptide. Library analyses demonstrated proteins that had motifs homologous to the peptide ligands, albeit with a high probability of a random match due to short peptide sequences. In summary, we applied the in vitro phage display technique to identify high-affinity peptide ligands to AQP2-expressing membranes. Library analyses identified proteins having homologous motifs, which need to be examined for involvement in AQP2 trafficking and regulation.</P>
]]></description>
<dc:creator><![CDATA[Lee, Y.-J., Choi, H.-J., Lim, J.-S., Earm, J.-H., Lee, B.-H., Kim, I.-S., Frokiaer, J., Nielsen, S., Kwon, T.-H.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00006.2008</dc:identifier>
<dc:title><![CDATA[A novel method of ligand peptidomics to identify peptide ligands binding to AQP2-expressing plasma membranes and intracellular vesicles of rat kidney]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F309</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F300</prism:startingPage>
<prism:section>INNOVATIVE METHODOLOGYS</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F310?rss=1">
<title><![CDATA[Contribution of intrarenal cells to cellular repair after acute kidney injury: subcapsular implantation technique]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F310?rss=1</link>
<description><![CDATA[ 
<P>The kidney is capable of regeneration following injury, particularly following acute insults. Although the mechanisms underlying cellular regeneration are incompletely understood, emerging evidence suggests a role for cells of renal origin in the repair and replacement of damaged renal tubule cells. The overall hypothesis of this study is that native kidney cells that reside in a niche in the kidney provide robust contribution to the repair of kidney tubules following injury. To test this hypothesis, we utilized a model of renal ischemia-reperfusion injury that results in extensive morphological changes, particularly in the outer medulla. Renal tissue obtained from mice constitutively expressing <I>Escherichia coli</I> &beta;-galactosidase (ROSA26) was dissected from the cortex, outer medulla, or papilla and implanted under the renal capsule of the injured mice. Mice were allowed to recover for 7 days. Sections through the injured kidney demonstrated the presence of implant-derived cells in renal tubules in the outer medulla. The implanted renal region that exhibited the most robust response was the papilla, whereas tissue pieces from the cortex and outer medulla showed less contribution to recipient renal tubules. These results provide proof-of-principle evidence that renal-derived reparative cells reside in all regions of the kidney, perhaps more predominantly in the renal papilla. A greater understanding of the cell biology of renal repair by native kidney cells will provide further insight into the design of novel therapies in acute kidney injury, and the subcapsular implant technique described in this study may offer unique advantages to evaluate renal repair mechanisms.</P>
]]></description>
<dc:creator><![CDATA[Curtis, L. M., Chen, S., Chen, B., Agarwal, A., Klug, C. A., Sanders, P. W.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.90205.2008</dc:identifier>
<dc:title><![CDATA[Contribution of intrarenal cells to cellular repair after acute kidney injury: subcapsular implantation technique]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F314</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F310</prism:startingPage>
<prism:section>INNOVATIVE METHODOLOGYS</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/295/1/F315?rss=1">
<title><![CDATA[Bioluminescence imaging to monitor the in vivo distribution of administered mesenchymal stem cells in acute kidney injury]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/295/1/F315?rss=1</link>
<description><![CDATA[ 
<P>Effective and targeted delivery of cells to injured organs is critical to the development of cell therapies. However, currently available in vivo cell tracking methods still lack sufficient sensitivity and specificity. We examined, therefore, whether a highly sensitive and specific bioluminescence method is suitable to noninvasively image the organ distribution of administered mesenchymal stem cells (MSCs) in vivo. MSCs were transfected with a luciferase/neomycin phosphotransferase construct (luc/neo-MSC). Bioluminescence of these cells was measured (charge-coupled device camera) after treatment with luciferin, showing a linear increase of photon emission with rising cell numbers. To track these cells in vivo, groups of mice were injected with 1 <FONT FACE="arial,helvetica">x</FONT> 10<SUP>5</SUP> luc/neo-MSCs/animal and imaged with bioluminescence imaging at various time points. Injection of cells in the suprarenal aorta showed diffuse distribution of cells in normal animals, whereas distinct localization to the kidneys was observed in mice with ischemia- and reperfusion-induced acute kidney injury (AKI). Intrajugular infusion of MSCs demonstrated predominant accumulation of cells in both lungs. In animals with AKI, detectable cell numbers declined over time, as assessed by bioluminescence imaging and confirmed by PCR, a process that was associated with low apoptosis levels of intrarenally located MSCs. In conclusion, the described bioluminescence technology provides a sensitive and safe tool for the repeated in vivo tracking of infused luc/neo-MSCs in all major organs. This method will be of substantial utility in the preclinical testing and design of cell therapeutic strategies in kidney and other diseases.</P>
]]></description>
<dc:creator><![CDATA[Togel, F., Yang, Y., Zhang, P., Hu, Z., Westenfelder, C.]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00098.2008</dc:identifier>
<dc:title><![CDATA[Bioluminescence imaging to monitor the in vivo distribution of administered mesenchymal stem cells in acute kidney injury]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F321</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F315</prism:startingPage>
<prism:section>INNOVATIVE METHODOLOGYS</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/full/295/1/F322?rss=1">
<title><![CDATA[CORRIGENDUM]]></title>
<link>http://ajprenal.physiology.org/cgi/content/full/295/1/F322?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2008-07-08</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.zh2-5212-corr.2008</dc:identifier>
<dc:title><![CDATA[CORRIGENDUM]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>F322</prism:endingPage>
<prism:publicationDate>2008-07-01</prism:publicationDate>
<prism:startingPage>F322</prism:startingPage>
<prism:section>CORRIGENDA</prism:section>
</item>

</rdf:RDF>